GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Panacea Biotec Ltd (BOM:531349) » Definitions » Gross Margin %

Panacea Biotec (BOM:531349) Gross Margin % : 55.27% (As of Dec. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Panacea Biotec Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Panacea Biotec's Gross Profit for the three months ended in Dec. 2023 was ₹832 Mil. Panacea Biotec's Revenue for the three months ended in Dec. 2023 was ₹1,505 Mil. Therefore, Panacea Biotec's Gross Margin % for the quarter that ended in Dec. 2023 was 55.27%.

Warning Sign:

Panacea Biotec Ltd gross margin has been in long-term decline. The average rate of decline per year is -7.1%.


The historical rank and industry rank for Panacea Biotec's Gross Margin % or its related term are showing as below:

BOM:531349' s Gross Margin % Range Over the Past 10 Years
Min: 38.99   Med: 61.11   Max: 68.07
Current: 51.89


During the past 13 years, the highest Gross Margin % of Panacea Biotec was 68.07%. The lowest was 38.99%. And the median was 61.11%.

BOM:531349's Gross Margin % is ranked worse than
59.07% of 750 companies
in the Biotechnology industry
Industry Median: 60.53 vs BOM:531349: 51.89

Panacea Biotec had a gross margin of 55.27% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Panacea Biotec was -7.10% per year.


Panacea Biotec Gross Margin % Historical Data

The historical data trend for Panacea Biotec's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Panacea Biotec Gross Margin % Chart

Panacea Biotec Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 55.19 67.50 63.00 54.49 38.99

Panacea Biotec Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 58.52 33.62 57.54 59.31 55.27

Competitive Comparison of Panacea Biotec's Gross Margin %

For the Biotechnology subindustry, Panacea Biotec's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Panacea Biotec's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Panacea Biotec's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Panacea Biotec's Gross Margin % falls into.



Panacea Biotec Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Panacea Biotec's Gross Margin for the fiscal year that ended in Mar. 2023 is calculated as

Gross Margin % (A: Mar. 2023 )=Gross Profit (A: Mar. 2023 ) / Revenue (A: Mar. 2023 )
=1781.6 / 4569.19
=(Revenue - Cost of Goods Sold) / Revenue
=(4569.19 - 2787.58) / 4569.19
=38.99 %

Panacea Biotec's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=831.8 / 1505
=(Revenue - Cost of Goods Sold) / Revenue
=(1505 - 673.2) / 1505
=55.27 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Panacea Biotec  (BOM:531349) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Panacea Biotec had a gross margin of 55.27% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Panacea Biotec Gross Margin % Related Terms

Thank you for viewing the detailed overview of Panacea Biotec's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Panacea Biotec (BOM:531349) Business Description

Traded in Other Exchanges
Address
Mathura Road, B-1 Extn./G-3, Mohan Co-operative Industrial Estate, New Delhi, IND, 110 044
Panacea Biotec Ltd is a Biotechnology company. It is engaged in the business of research, development, manufacturing, and marketing of branded pharmaceutical formulations, vaccines, and biopharmaceuticals. The company's operating segments include Vaccines, and Formulations. It generates maximum revenue from the Vaccines segment. The company product portfolio includes prescription products in niche therapeutic areas such as diabetes and cardiovascular management, oncology, nephrology and transplant management, osteoporosis management, gastro-intestinal care, pain management products, and pediatric immunization. The group has a business presence in India and Outside India.

Panacea Biotec (BOM:531349) Headlines

No Headlines